Holen Sie sich die Stockscreener-App
277.22
2.43%
6.58
Handel nachbörslich:
277.22
Schlusskurs vom Vortag:
$270.64
Offen:
$274
24-Stunden-Volumen:
728.38K
Relative Volume:
1.59
Marktkapitalisierung:
$10.53B
Einnahmen:
$1.16B
Nettoeinkommen (Verlust:
$34.55M
KGV:
322.35
EPS:
0.86
Netto-Cashflow:
$134.18M
1W Leistung:
+1.82%
1M Leistung:
-1.13%
6M Leistung:
+34.82%
1J Leistung:
+36.56%
1-Tages-Spanne:
$270.02
$277.22
1-Wochen-Bereich:
$268.15
$280.77
52-Wochen-Spanne:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Vergleichen Sie PEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
277.22 | 10.53B | 1.16B | 34.55M | 134.18M | 0.86 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
What To Expect From Penumbra’s (PEN) Q1 Earnings - Yahoo Finance
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GlobeNewswire
Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits (PR Newswire) - Aktiellt
Penumbra CEO Adam Elsesser sells $4.54 million in stock By Investing.com - Investing.com South Africa
Penumbra CEO Adam Elsesser sells $4.54 million in stock - Investing.com
Penumbra director O’Rourke sells shares worth $13,560 By Investing.com - Investing.com South Africa
Penumbra director O’Rourke sells shares worth $13,560 - Investing.com
Investors more bullish on Penumbra (NYSE:PEN) this week as stock lifts 6.4%, despite earnings trending downwards over past five years - simplywall.st
Penumbra (PEN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
RBC Lifts Price Target on Penumbra to $315 From $313, Keeps Outperform Rating - marketscreener.com
BTIG Adjusts Penumbra (PEN) Price Target as MedTech Q1 Results L - GuruFocus
Micro Guide Catheters Market to Witness Remarkable Growth with - openPR.com
Truist Adjusts Price Target for Penumbra (PEN) Amid Market Volat - GuruFocus
Truist Cuts Price Target on Penumbra to $315 From $325, Keeps Buy Rating - MarketScreener
Penumbra price target lowered to $315 from $325 at Truist - TipRanks
Is Penumbra Gaining or Losing Market Support? - Benzinga
3 Reasons PEN is Risky and 1 Stock to Buy Instead - The Globe and Mail
PEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Penumbra, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm - marketscreener.com
Reasons to Retain Penumbra Stock in Your Portfolio for Now - MSN
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Penumbra, Inc. (NYSE: PEN) - PR Newswire
(PEN) Trading Report - news.stocktradersdaily.com
Penumbra Inc director Wilder Thomas sells $96,094 in stock By Investing.com - Investing.com India
Penumbra CEO Adam Elsesser sells $4.5 million in stock By Investing.com - Investing.com South Africa
Penumbra CEO Adam Elsesser sells $4.5 million in stock - Investing.com
Penumbra Inc director Wilder Thomas sells $96,094 in stock - Investing.com
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 - BioSpace
Penumbra Q1 2025 Earnings Date Confirmed: Key Details for Investors - Stock Titan
Penumbra EVP Johanna Roberts sells $161,466 in stock By Investing.com - Investing.com Australia
Penumbra director Harpreet Grewal sells $53,434 in stock By Investing.com - Investing.com Canada
Penumbra director Wilder Thomas sells $95,248 in common stock - Investing.com
Penumbra director Harpreet Grewal sells $53,434 in stock - Investing.com
Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vac - GuruFocus
Breakthrough Clinical Data: Penumbra's CAVT Slashes Hospital Stays by 46%, Achieves 99% Success Rate - Stock Titan
Meiji Yasuda Asset Management Co Ltd. Buys New Position in Penumbra, Inc. (NYSE:PEN) - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages Penumbra, Inc. Investors to Secure Counsel Before Important March 16 DeadlinePEN - PR Newswire
Penumbra Insider Sold Shares Worth $3,405,253, According to a Recent SEC Filing - MarketScreener
Penumbra director Arani sells $3.41 million in stock - Investing.com India
Thrombectomy Devices Market Surge: Key Players & Future Outlook - openPR.com
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues - MSN
Imperative Care Expands Precision Thrombectomy Portfolio - Diagnostic and Interventional Cardiology
Penumbra CEO Adam Elsesser sells $4.59 million in stock By Investing.com - Investing.com Australia
Penumbra CEO Adam Elsesser sells $4.59 million in stock - Investing.com
Do Its Financials Have Any Role To Play In Driving Penumbra, Inc.'s (NYSE:PEN) Stock Up Recently? - Yahoo Finance
Has Penumbra, Inc.'s (NYSE:PEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - simplywall.st
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):